Special Issue

Gynecological Oncology: From Pathogenesis to Therapy

Message from the Guest Editor

Gynecological oncology stands at the intersection of medicine, science, and compassion, and is dedicated to understanding and combating the complexities of cancers that affect the female reproductive system. From the ovaries and cervix to the uterus and beyond. this field encompasses a diverse array of malignancies. The journey from pathogenesis to therapy in gynecological oncology is a multifaceted one, and is fraught with challenges and complexities. Despite advances in research and technology, many aspects of these cancers remain enigmatic, particularly concerning rare subtypes and aggressive variants that are resistant to conventional treatments. Moreover, the landscape of gynecological oncology is continually evolving, and it is shaped by emerging trends in personalized medicine, immunotherapy, and the integration of multidisciplinary approaches. In this Special Issue, we aim to focus on gynecological oncology and explore the latest advancements in our understanding of the pathogenesis of these malignancies, the evolving landscape of diagnostic modalities, and the diverse armamentarium of therapeutic strategies at our disposal.

Guest Editor

Dr. Stefano Cianci

Associate Professor in Department of Human Pathology of Adult and Childhood "G. Barresi", Unit of Gynecology and Obstetrics, University of Messina, Messina, Italy

Deadline for manuscript submissions

closed (25 September 2024)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/196667

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

